Because we speculated FDFT1 as a tumor suppressor in CRC, we assessed the expression of FDFT1 with that of AKT1, mTOR, HIF1α, GLUT1, and HK2. The patients with a high expression of FDFT1 and a low expression of AKT1, mTOR, HIF1α, GLUT1, and HK2 exhibited longer survival than those with a low expression of FDFT1 and a high expression of the AKT-mTOR-HIF1α pathway and glycolytic genes (Fig. 7f–j; Supplementary Fig. 27). This evidence concerns the gene SLC2A1 and colorectal carcinoma.